Key result
IV disopyramide shows no overall sinus node effect but markedly depresses function in severe bradycardia.
Why the study?
The electrophysiologic effects of intravenously administered disopyramide on sinus node function in patients with sinus node dysfunction were not well characterized.
Does intravenous disopyramide affect sinus node function in patients with sinus node dysfunction?
Does intravenous disopyramide affect sinus node function in patients with sinus node dysfunction?
Disopyramide should be administered cautiously in patients with sinus node dysfunction, as it can cause marked depression of sinus node function and SA exit block in a susceptible subset.
Answers are grounded in this paper and cite their sources.
May warrant caution with disopyramide in severe sinus node dysfunction; hypothesis-generating for targeted sinus node assessment.
The electrophysiologic effects of intravenously administered disopyramide (2 mg/kg) on three parameters of sinus node function were examined in 16 symptomatic patients with sinus node dysfunction. Based on their ECG data before study, patients were subdivided into group A (n = 8), those with sinus pauses and/or sinoatrial (SA) exit block; and group B (n = 8), those with sinus bradycardia. Disopyramide shortened spontaneous cycle length in 10 of 16 patients and lengthened it in six--markedly so (91%) in one patient. Estimated SA conduction time decreased in seven of 14 patients and increased in seven. Two patients developed second degree SA exit block after disopyramide. Maximum sinus node recovery time was prolonged by disopyramide in 11 of 16 patients and markedly so in four. For the group as a whole there was no significant difference in spontaneous cycle length, maximum sinus node recovery time or estimated SA conduction time. P-wave and QRS durations and H-V intervals were significantly lengthened by disopyramide. Marked depression of the three parameters of sinus node function occurred in three group A patients and in one group B patient who had persistent severe sinus bradycardia. These four patients also had secondary pauses after termination of rapid atrial pacing under control conditions. Disopyramide should be administered cautiously to patients with sinus node dysfunction, particularly those with sinus pauses, SA exit block or secondary pauses.
No takes yet. Share an insight, caveat, or question.
LaBarre et al. (1979) studied Sinus node dysfunction (n=16). Disopyramide phosphate vs. Baseline (before study) was evaluated on Spontaneous cycle length, maximum sinus node recovery time, and estimated SA conduction time. Intravenous disopyramide produced no significant overall difference in sinus node function parameters, but caused marked depression in patients with severe sinus bradycardia or sinus pauses.
Synapse has enriched 10 related papers. Consider them for comparative context: